Please assess the completion status of the following clinical trial:

Trial Title: A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 14.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women-not-of-childbearing potential diagnosed with type 2 diabetes for at least three months~* Stable treatment regimen with either metformin (at least 1500 mg) or diet and exercise alone for at least three months~* HbA1c: 7.0-10.0 % (both inclusive)~* Body weight between 60 kg and 110 kg~Exclusion Criteria:~* Treatment with insulin, GLP-1 receptor agonists (including liraglutide), dipeptidyl peptidase-4 inhibitors, sulphonylurea, thiazolidinediones, Alpha-GIs, or any investigational drug, within the last three months~* Impaired liver or kidney function~* Proliferative retinopathy or maculopathy requiring acute treatment~* Clinically significant active cardiovascular disease and uncontrolled treated/untreated hypertension~* Recurrent major hypoglycaemia or hypoglycaemic unawareness~* Present or planned use of any drug which could interfere with the glucose levels (e.g. systemic corticosteroids)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: EXPERIMENTAL): None
- C (Type: EXPERIMENTAL): None
- D (Type: EXPERIMENTAL): None
- E (Type: EXPERIMENTAL): None
- F (Type: EXPERIMENTAL): None
- G1 (Type: PLACEBO_COMPARATOR): None
- G2 (Type: PLACEBO_COMPARATOR): None
- G3 (Type: PLACEBO_COMPARATOR): None
- G4 (Type: PLACEBO_COMPARATOR): None
- G5 (Type: PLACEBO_COMPARATOR): None
- G6 (Type: PLACEBO_COMPARATOR): None
- H (Type: EXPERIMENTAL): None
- I (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).